In the current study, we used propensity score matching to reduce the selection bias and found that the residual tumor resection after partial response to EGFR-TKI or primary tumor resection followed by EGFR-TKI had clinical benefits in both PFS and OS. The gene discussed is EGFR; the disease is neoplasm.